Methyl isoeugenol

Name: Methyl isoeugenol
Brand: MedChemExpress
SKU: HY-N2439
Rating: 4.5 (1 reviews)

Cat. No.: HY-N2439 Purity: 98.11%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Methyl isoeugenol is an orally active, blood-brain barrier-permeable isoeugenol-type eugenol analog. Methyl isoeugenol promotes the nuclear translocation of Nrf2, upregulates the expressions of HO-1, NQO1 and SOD, and reduces the expression level of MDA. Methyl isoeugenol decreases the nuclear translocation of NF-κB. Methyl isoeugenol inhibits NLRP3 inflammasome-mediated pyroptosis. Methyl isoeugenol reduces cerebral infarction volume and regulates the M1/M2 phenotypic balance of microglia. Methyl isoeugenol can be used for the research of cerebral ischemia-reperfusion injury.

For research use only. We do not sell to patients.

Methyl isoeugenol Chemical Structure

CAS No. : 93-16-3

Size	Stock	Quantity
Liquid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Liquid
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Methyl isoeugenol:

Methyl isoeugenol (Standard) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
KB	IC₅₀	> 10 μg/mL Compound: 32	Cytotoxicity against human KB cells after 2 days by sulforhodamine B assay Cytotoxicity against human KB cells after 2 days by sulforhodamine B assay	[PMID: 17067159]
KB	IC₅₀	> 10 μg/mL Compound: 32	Cytotoxicity against multidrug-resistant human KB-VCR cells after 2 days by sulforhodamine B assay Cytotoxicity against multidrug-resistant human KB-VCR cells after 2 days by sulforhodamine B assay	[PMID: 17067159]

In Vitro

Methyl isoeugenol (0-100 μM; 23.5 h) inhibits the secretion of proinflammatory cytokines, the expression of proinflammatory mediators, and NLRP3 inflammasome-mediated pyroptosis in BV2 microglia induced by LPS (HY-D1056)-ATP (HY-B2176), with the strongest effect observed at the concentration of 100 μM^[1].
Methyl isoeugenol (25-100 μM; 23.5 h) inhibits LPS-ATP-induced oxidative stress in BV2 microglia, upregulates the Nrf2 antioxidant signaling pathway, and suppresses the nuclear translocation of NF-κB, with the strongest activity observed at the concentration of 100 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Methyl isoeugenol (25-100 mg/kg/day; p.o.; daily; 3 days) protects against cerebral ischemia-reperfusion injury in male SD rats, reducing infarct volume by up to 59.8%, improving neurological deficits, suppressing neuroinflammation and NLRP3 inflammasome-mediated pyroptosis, and activating the Nrf2 antioxidant signaling pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley (SD) (male, 260-280 g, induced by 2 hours of middle cerebral artery occlusion followed by 3 days of reperfusion)^[1]
Dosage:	25 mg/kg/day; 50 mg/kg/day; 100 mg/kg/day
Administration:	p.o.; daily; 3 days
Result:	Reduced cerebral infarct volume percentage to 29.06 and 33.03 at 50 mg/kg and 100 mg/kg, respectively. Reduced modified neurological severity scores to 6.80, 5.80, and 5.20 at 25 mg/kg, 50 mg/kg, and 100 mg/kg, respectively. Reduced serum IL-1β to 9.47 and 7.72, serum TNF-α to 23.48 and 24.13, and brain cortex IL-6 to 261.15 and 260.80 at 50 mg/kg and 100 mg/kg, respectively. Reduced brain cortex TNF-α to 243.84, reduced M1 microglial markers CD16/32 (0.15) and Iba1 (0.11), reduced NLRP3 inflammasome-related proteins NLRP3 (0.31), cleaved-caspase-1 (0.34), and GSDMD (1.61), and increased nuclear Nrf2 translocation (1.26) at 100 mg/kg vs. untreated injury controls. Increased serum SOD activity, decreased serum MDA levels, increased brain cortex SOD activity, and upregulated brain cortex HO-1 protein expression at all doses vs. untreated injury controls.

Molecular Weight

178.23

Formula

C₁₁H₁₄O₂

CAS No.

93-16-3

Appearance

Liquid (Density: 1.05 g/cm³)

Color

Colorless to light yellow

SMILES

C/C=C/C1=CC=C(OC)C(OC)=C1

Structure Classification

Others

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (561.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	5.6107 mL	28.0536 mL	56.1073 mL
5 mM	1.1221 mL	5.6107 mL	11.2215 mL
10 mM	0.5611 mL	2.8054 mL	5.6107 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 98.11%

Select Batch:

Data Sheet (273 KB) SDS (254 KB)

COA (246 KB) HNMR (236 KB) LCMS (91 KB)

Handling Instructions (2659 KB)

References

[1]. Liu H, et al. Methyl isoeugenol suppresses NLRP3 inflammasome-mediated pyroptosis via activation of Nrf2/NQO1/HO-1 signaling in cerebral ischemia-reperfusion injury. Biochem Pharmacol. 2025;237:116947.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	5.6107 mL	28.0536 mL	56.1073 mL	140.2682 mL
	5 mM	1.1221 mL	5.6107 mL	11.2215 mL	28.0536 mL
	10 mM	0.5611 mL	2.8054 mL	5.6107 mL	14.0268 mL
	15 mM	0.3740 mL	1.8702 mL	3.7405 mL	9.3512 mL
	20 mM	0.2805 mL	1.4027 mL	2.8054 mL	7.0134 mL
	25 mM	0.2244 mL	1.1221 mL	2.2443 mL	5.6107 mL
	30 mM	0.1870 mL	0.9351 mL	1.8702 mL	4.6756 mL
	40 mM	0.1403 mL	0.7013 mL	1.4027 mL	3.5067 mL
	50 mM	0.1122 mL	0.5611 mL	1.1221 mL	2.8054 mL
	60 mM	0.0935 mL	0.4676 mL	0.9351 mL	2.3378 mL
	80 mM	0.0701 mL	0.3507 mL	0.7013 mL	1.7534 mL
	100 mM	0.0561 mL	0.2805 mL	0.5611 mL	1.4027 mL